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Mapping autism risk loci using genetic linkage and
chromosomal rearrangements
The Autism Genome Project Consortium1
Autism spectrum disorders (ASDs) are common, heritable neurodevelopmental conditions. The genetic architecture of ASDs is
complex, requiring large samples to overcome heterogeneity. Here we broaden coverage and sample size relative to other studies
of ASDs by using Affymetrix 10K SNP arrays and 1,181 families with at least two affected individuals, performing the largest
linkage scan to date while also analyzing copy number variation in these families. Linkage and copy number variation analyses
implicate chromosome 11p12–p13 and neurexins, respectively, among other candidate loci. Neurexins team with previously
implicated neuroligins for glutamatergic synaptogenesis, highlighting glutamate-related genes as promising candidates for
contributing to ASDs.
Autism is a neurodevelopmental disorder characterized by impair-
ments in reciprocal social interaction, communication deficits and
repetitive and restricted patterns of behavior and interests. Autistic
disorder is the prototypical pervasive developmental disorder (PDD
or, equivalently, ASD), which form a group that also includes Asperger
disorder, PDD not otherwise specified and Rett disorder1. Population
prevalence of autism is approximately 15–20 in 10,000, and all ASDs
affect about 60 in 10,000 children. Worldwide, males are affected four
times as often as females2. Autism is associated with a recognized
cause in only about 10% of individuals, most commonly with fragile X
syndrome, tuberous sclerosis and chromosomal abnormalities3,4.
Twin studies show a concordance of 60%–92% for monozygotic
twins and 0%–10% for dizygotic pairs, depending on phenotypic
definitions5. Milder phenotypes are similarly elevated in relatives of
singleton probands, consistent with a spectrum of severity6. The
estimated prevalence of autism in siblings is 5%–10% (refs. 7,8).
The ratio of sibling recurrence risk to population prevalence varies
from 67 to 25, both larger than for most multifactorial diseases.
Although familial clustering in autism could reflect shared environ-
mental factors, twin studies5,9 and the distribution of milder pheno-
types in families favors a model involving multiple interacting loci10,11.
We hypothesize that liability to autism is due, in large part, to
oligogenic inheritance in which combinations of susceptibility alleles
contribute. Variation in phenotypic severity of sibling pairs and family
members ascertained through an autistic proband are both consistent
with this hypothesis. Based on numerous observations of karyotypic
abnormalities in autism, we also hypothesize that submicroscopic
alterations are involved.
Genome-wide linkage scans12 (also reviewed in ref. 13) for autism
susceptibility loci have identified chromosomal regions 2q, 7q and
17q, with 7q yielding the most consistently positive results, including
support from meta-analysis. Moreover, substantial evidence suggests
that chromosomal abnormalities contribute to autism risk, but the
exact prevalence is unclear because literature surveys span different
diagnostic and cytogenetic approaches and sample sizes. Recent
surveys3,4 show a mean rate of gross mutations and chromosomal
abnormalities between 4.3% (78/1,826) and 7.4% (129/1,749), but
many studies find rates of detected abnormalities in 5%–10% of
affected individuals3. Among the most frequent findings are
fra(X)(q27) (3.1%; 28/899) and anomalies involving proximal 15q
(0.97%; 17/1,749), specifically the Prader-Willi and Angelman
region3,4. Duplications of 15q11–q13, typically of maternal origin,
are observed in 1%–3% of cases, either as interstitial duplications or
supernumerary isodicentric marker chromosomes containing one or
two extra copies of this region3. Linkage, association, and/or chromo-
some rearrangement studies have identified several ASD candidates,
including genes encoding neuroligins and their binding partners, as
having disease-associated mutations14–17.
In our model for autism, combinations of multiple loci that
possibly interact and microscopic or submicroscopic chromosomal
abnormalities contribute to risk, complicating the detection of indi-
vidual loci. Increasing the likelihood of detecting loci requires analyz-
ing a large sample of multiplex families (i.e., families with two or more
affected individuals), thereby enhancing the power of linkage analysis
and controlling sources of etiologic heterogeneity (herein, the term
families implies multiplex families).
We have assembled a sample of over 1,400 ASD families, a resource
sufficiently large to implement multiple strategies for localizing
susceptibility loci (see ‘Power’ in Supplementary Methods online).
Although some linkage studies have attempted to control for hetero-
geneity attributable to chromosomal abnormalities by excluding the
small number of affected families, none has attempted to merge
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linkage analysis with studies of fine-level chromosomal variation. We
have developed an approach, using comparative analysis of hybridiza-
tion intensities, to identify submicroscopic copy number variations
(CNVs) as putative risk loci and as a tool to stratify the samples to
reduce genetic heterogeneity for linkage analyses.
RESULTS
Individuals with ASD
The Autism Genome Project (AGP) Consortium, comprising scientists
from 50 centers in North America and Europe, collected 1,496 ASD
families (7,917 family members) for this study. Diagnosis was based
on the Autism Diagnostic Interview-Revised (ADI-R) and the Autism
Diagnostic Observation Schedule (ADOS) or clinical evaluation (see
ref. 18 and Methods). Origins of the individuals screened are shown in
Supplementary Methods; most were karyotyped (B71%) and
screened for fragile X mutations (B94%), and families were excluded
if either was abnormal in at least one affected individual. Most cell
lines or DNA samples arising from the project are available at the
National Institute for Mental Health (NIMH) Center for Collaborative
Genetic Studies, the European Collection of Cell Cultures and the
Autism Genetics Research Exchange. We genotyped genomic or in
some cases whole genome–amplified (WGA) DNA.
Linkage analysis by diagnostic group
We successfully generated genotypes from 1,491 of 1,496 nominal
families (6,709 samples; Table 1) using the Affymetrix 10K v2 SNP
array. WGA had no discernible impact on genotyping accuracy: for 12
duplicate samples assessed, concordance of genotypes for WGA versus
blood DNA was 499.6% with no significant difference in completion
rates (bothB94%). From the 10,112 SNPs initially genotyped, quality
control procedures resulted in marker exclusion for the following
reasons: minor allele frequency o0.05 (removed 749 SNPs), high
rate of missing genotypes (removed 1,112 SNPs), selection of tag
SNPs (removed 1,734 SNPs) and deviations from Hardy-Weinberg
Equilibrium (removed 391 SNPs). Following quality control, the
discordant call rate per locus, based on 261 duplicate samples, was
roughly 5/10,000.
Quality control on family data had a similar impact on reducing
numbers (Table 1), yielding 1,181 families for linkage analysis. Of
these families, we estimate that 64% were included in smaller,
published linkage studies. The families were distributed across three
diagnostic categories (narrow, broad and heterogeneous ASD
(hASD)), which were defined according to the distribution of diag-
nosis (see Methods). Linkage analyses were performed for three nested
diagnostic groupings (narrow, broad and all families); for analyses
focusing on one diagnostic group, ‘broad’ is a
reasonable choice because a substantial num-
ber of families fall in the group, and the
sensitivity and specificity of this diagnostic
method are reliable18.
Before linkage analyses, we rebuilt the
Affymetrix genetic map by linear inter-
polation from National Center for Biotech-
nology Information Build35 and markers of
known genetic positions19 to infer genetic
locations for all SNPs. We then validated the
new genetic map using the linkage data.
Linkage information, as reported by
MERLIN, averaged B95% over the genome
(minima at telomeres, Z71%) because of
high coverage of markers across the genome
and availability of parental genotypes (3% of families have no parental
genotypes, whereas 79% have genotypes for both parents). Thus, the
results are also insensitive to SNPs in linkage disequilibrium (see
Methods). Only for all families does statistical evidence exceed the
threshold for suggestive linkage20, at 11p12–p13 (Fig. 1).
Characterization of copy number variation
We assessed our samples for CNV content using signal intensities
obtained from the SNP arrays. Because the distribution of intensity is
continuous, whereas copy numbers are discrete, an algorithm is
required to infer copy number from signal intensity of a SNP genotype
relative to intensity from other samples. Initially, to capture as many
CNVs as possible, we used two approaches (termed ‘batch’ and ‘plate-
by-plate’) for intensity comparisons, which yielded a total of 2,788
putative CNVs from 1,109 samples from 715 families (Table 2). To
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Table 1 Families at each stage of quality control
Narrow Broad hASD Total
Diagnostic data Z 2 affected 675 942 554 1,496
Genotypic data Z 2 genotyped 675 942 549 1,491
Diagnostic and genotypic data Z 2 affected and genotyped 597 829 488 1,317
Edit 1 Z 2 affected and genotyped 564 787 461 1,248
Edit 2 Z 2 affected and genotyped 554 772 450 1,222
Edit 3 Z 2 affected and genotyped 528 739 442 1,181
Quality control of samples was based on genotypes determined by the Affymetrix 10K array, which contains 10,112
SNPs. See Supplementary Methods for origin of sample by research center. Edit 1: eliminated pedigrees and samples
incompatible with linkage assumptions (monozygotic twins and inconsistent nominal or genetic relationships). Edit 2:
dropped loci missing Z10% of their genotype calls and then dropped individuals missing Z20% of their genotype
calls (rates determined empirically based on the frequency distribution of missing genotypes). Edit 3: removed
duplicate individuals and families who contributed DNA to more than one center. Most families were nuclear; after
Edit 3, the number of marriages per family was 1.26, 1.24 and 1.16 for the ‘narrow’, ‘broad’ and ‘hASD’ categories.
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Figure 1 Linkage across the genome for all families and ancestries,
based on levels of diagnostic certainty. Vertical reference lines separate
chromosomes, which are ordered. The horizontal reference bar is given at
a Zlr of 3.18, the threshold for suggestive linkage according to the Lander/
Kruglyak criterion20, which is roughly accurate in this setting (4.1 is the
threshold for significant linkage). The suggestive threshold would be
expected to be crossed by chance once per genome scan. It is crossed
once, and the peak falls within 11p12 (Zlr ¼ 3.57 at rs2421826).
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define a more stringent set of CNV calls, we examined the raw
intensity data from 42 CNV calls that were presumed real based on
overlap with non-mendelian genotype errors or by laboratory experi-
mentation. We also assessed samples having identical CNVs within the
same family, as these could also be considered to be validated calls.
These analyses showed that our plate-by-plate
signal intensity comparison had less back-
ground and was likely to contain fewer
false-positive data compared with the batch
approach (see Methods and ref. 21). There-
fore, we then scrutinized these intensity files
to guide threshold settings to define a highly
stringent data set, called ‘filtered,’ containing
624 CNVs from 350 different families (Sup-
plementary Table 1 online and Fig. 2).
Caveats about these data are as follows:
(i) there will be bona fide CNVs in the batch
comparison data that fail to meet cutoffs in
the filtered analysis; (ii) some CNVs could be
somatic artifacts, such as cell culture–induced
rearrangements and aneuploidy; (iii) the
mapping resolution of CNV boundaries is
dependent on local SNP density and is there-
fore nonuniform; (iv) smaller CNVs will be
more likely to be missed (Supplementary
Fig. 1 online) and (v) balanced rearrange-
ments will not be detected.
Considering solely our highest confidence
data, we identified 254 CNVs in 196 ASD
cases from 173 families (Table 2, Fig. 2 and
Supplementary Tables 2 and 3 online). The
average and median sizes were 3.4 Mb and
0.66 Mb, respectively, and the majority (66%)
were CNV gains, probably owing to a greater
tolerance in the genome for large gains versus
deletions. The observations most relevant to
ASD disease risk (Supplementary Table 1)
included (i) the identification of ten families
with apparent de novo CNVs (in three such
families, the CNV was found in both ASD
sibs); (ii) 18 CNVs in unrelated affected
individuals having genomic locations coinci-
dent with published ASD chromosome rear-
rangements and (iii) 126 CNVs with
recurrent (47) or overlapping (79) bound-
aries, suggesting they could be nonrandom
events (Supplementary Tables 3 and 4
online). We also detected seven samples
from three families with ASD-associated
chromosome 15q gains, all of which were
maternally inherited, as would be expected
(including at least two that escaped earlier
karyotypic detection).
We highlight four CNV discoveries to
demonstrate the utility and complexity of
this data and also to serve as a prototype of
how this new type of genetic information can
be used in mapping studies. First, in family
AS049, two female sibs with ASD had appar-
ently identical 300-kb CNV losses of chromo-
some 2p16 not detected in either parent.
Quantitative PCR analysis confirmed the microdeletion: microsatellite
analysis showed the identical maternal chromosomal segment but no
paternal DNA in the sibs, providing a likely explanation of paternal
gonadal mosaicism. This hemizygous deletion eliminates coding exons
from the neurexin 1 gene (NRXN1), which represents a functional
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Table 2 Characteristics of CNVs found in multiplex autism families using different
stringencies of analysis
Methoda
Features Batchb Plate-by-platec
Filtered based
on thresholdsd
Total samples
Number of CNVs 1,967 1,286 624
Number of samples 918 685 490
Number of CNVs/sample 2.14 1.88 1.28
Number of families 590 476 350
Mean/median sizee 4.6/1.8 Mb 3.4/1.2 Mb 3.9/0.6 Mb
Gain/loss of CNV 1,749/228 1,064/232 402/222
Unaffected individuals
Number of CNVs 1,186 802 370
Number of samples 538 425 292
Number of CNVs/sample 2.20 1.86 1.25
Number of families 419 329 235
Mean/median sizee 4.7/1.9 Mb 3.6/1.3 Mb 4.3/0.69 Mb
Gain/loss of CNV 1,054/133 658/143 235/136
Affected individuals
Number of CNVs 781 495 254
Number of samples 380 260 196
Number of CNVs/sample 2.06 1.90 1.29
Number of families 322 230 173
Mean/median sizee 4.6/1.8 Mb 3.2/1.2 Mb 3.4/0.66 Mb
Gain/loss of CNVs 685/96 406/89 167/86
Inherited CNVs (number of regions)f 78 (62) 59 (46) 49 (39)
Sibling CNVs (number of regions)g 68 (34) 36 (18) 34 (17)
De novo CNVs (siblings)h 33 (26) 16 (10) 10 (6)
Familial recurrent CNVs (number of regions)i 28 (14) 16 (8) 14 (7)
Recurrent CNVs (number of regions)j 209 (66) 135 (43) 47 (18)
Overlapping CNVsk 422 251 79
Nonoverlapping CNVs 139 109 128
CNVs overlapping with ACRDl 68 27 18
CNVs overlapping with DGVm 20 10 9
CNVs validated (in affected)n 326 (162) 230 (106) 193 (95)
Number of families removed for linkage
analysis modelingo
267 200 150
a,b,c,dCNV analysis for the arrays was performed using three approaches: after trimming the data set with the first-pass
cutoffs, arrays were renormalized and analyzed using a ‘batch comparison’ (B1,000 scans; footnote b) or by a ‘plate-by-plate’
comparison (96 scans; footnote c) to avoid potential plate-specific batch effects. In the most stringent analysis (footnote d),
thresholds were set based on validation data (see footnote n below) to minimize potential for false positives. We note that
although column 4 contains data from the most stringent analysis, there are some CNVs found exclusively in one or both of
columns 2 and 3 that are indeed real. All data can be viewed at the Autism Chromosome Rearrangement Database (see URL in
Methods). eRange of CNV size: batch (100 bp to 240 Mb), plate-by-plate (100 bp to 134 Mb), filtered (100 bp to 134 Mb);
distributions are shown in Supplementary Figure 1. fCNVs in affected individuals that were inherited from either parent. gCNVs
present in two or more affected siblings that are either de novo or inherited. hCNVs in affected individuals that are de novo in
origin with the total number of de novo events occurring in siblings in brackets. iCNVs that are familial and recurrent. jCNV gains
or CNV losses with the same coordinates found in two or more unrelated families (a recurrent CNV gain and CNV loss at the same
site is only counted once). kTwo or more CNV gains or CNV losses with overlapping genomic coordinates (a CNV gain and CNV
loss combination is not counted). lCNVs that overlap with mapped chromosome rearrangement breakpoints annotated in the
Autism Chromosome Rearrangement Database. mCNVs that overlap with other CNVs not known to be associated with disease
as catalogued in the Database of Genomic Variants (see URL in Methods). We note that some CNVs found in the DGV could
be predisposing or disease related. nTotal number of validated CNVs. A CNV was considered validated if it overlapped with
mendelian genotype errors or if it was confirmed using an independent set of experiments (for example, karyotyping, quantitative
PCR, array-CGH or Affymetrix 500K Mapping arrays) (Supplementary Table 4). oNumber of families belonging to the group of
1,168 families passing data cleaning that were removed from linkage analysis. Families were only removed if at least one
affected individual contained a CNV not found in the Database of Genomic Variants.
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candidate for ASD based on the role of NRXN1 in synaptogenesis and
its interaction with neuroligins. Rare NRXN1 mutations apparently
generate risk for ASD and mental retardation16,22,23. Both girls
presented with typical autism, including characteristic developmental
delays. Although we could not be certain of their verbal status
because of their young age, one appeared nonverbal, whereas her
sister had mild language regression. Neither parent had clinically
important features.
Second, we found a recurring 1.1-Mb CNV gain at chromosome
1q21 in three families: AS048, with one affected male; AS039, one
affected female; and AS007, two affected male sibs and their father of
unknown affection status. It overlaps the same region implicated in
mental retardation and other anomalies21,24,25.
Third, we observed CNVs of B933 kb at 17p12 as a de novo
duplication in an affected male-female sib pair in one family (AS068),
as a maternally inherited deletion in two affected male sibs (AS028)
and as a paternally inherited deletion in an affected female (AS001).
This interval, when duplicated, causes Charcot-Marie-Tooth 1A
(CMT1A) and when deleted causes hereditary neuropathy with
liability to pressure palsy26. This region also overlaps with micro-
deletions seen in some cases of Smith-Magenis syndrome, which itself
has phenotypic overlap with ASDs27. Moreover, other microduplica-
tions of the same interval have been described in individuals with
mental retardation, speech and language delay, autism and related
phenotypes28. None of the implied disease-associated CNVs described
above were observed in any known control sample database,
which at the time of the study comprised B500 samples from the
general population21,29.
Finally, we detected further complexity in two families with
duplications of 22q11.2. In family AS063, the male proband diagnosed
with autism inherited the duplication from his father, but a brother
with PDD not otherwise specified does not have the duplication. In
family AS019, the female sib diagnosed with autism carried the
duplication, whereas an affected brother did not, and we did not
observe the duplication in either parent. Genotyping confirmed the
biological parents. FISH analysis confirmed duplications in both
families and showed that it was de novo in the second family (data
not shown).
Exploration of linkage by subsets of the data
Linkage analysis identifies regions harboring one or more genetic
variants that account for a substantial portion of risk in families. Rare
de novo or familial CNVs that confer risk for ASDs could be a source
of noise or heterogeneity that decreases sensitivity in linkage analyses.
Thus, in theory, linkage signals from major loci could be amplified if
families with rare CNV risk alleles were removed. A sound strategy to
evaluate subsets based on known and putative CNVs, however, is
unclear. Consider our three levels of CNV discovery (namely, filtered,
plate and batch), which are ordered by degree of stringency of
evidence required to call a CNV. Moving from filtered to batch, it is
reasonable to assume that the rate of false positives is increasing while
the rate of false negatives is potentially decreasing. Selecting a single
approach a priori favors a certain, unknown ratio of false positives to
false negatives. This ratio might not be optimal, depending on how
much of the attributable risk for ASDs accrues to CNVs: if CNVs
account for a large fraction of the risk, the false negative rate is critical;
conversely, if CNVs account for a small fraction of the risk, then the
false positive rate is of greater importance. For this reason, we chose to
explore the effects of all three levels of CNV discovery. Within each
level, we removed families in which at least one individual was
diagnosed with ASD and also carried at least one putative CNV
(Table 3). Using the broad diagnostic group, we recomputed the
linkage traces (Supplementary Fig. 2 online).
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Figure 2 Chromosome ideogram depicting 253 inferred CNVs found in 196
individuals with ASDs. These CNVs are derived from the highest stringency
‘filtered’ data set, but many other true CNVs will also be found in the
other analyses and should be examined further. Characteristics of the
complete data set are described in Table 2. Some of the larger changes
could represent somatic artifacts or missed karyotypic anomalies. All data
are also downloadable or can be viewed in Genome Browser format at the
Autism Chromosome Rearrangement Database (see URL in Methods). As
additional analyses and validations are performed, the data will be posted
at the same site.
Table 3 Number of families by diagnostic group, gender of ASD
individuals and CNV-calling method
Diagnostic groupa Familiesa Total Filtered Plate Batch
Narrow All 528 462 431 406
MO 334 296 274 259
FC 194 166 157 147
Broad All 739 641 603 567
MO 464 408 382 359
FC 275 233 221 208
All All 1,181 1,031 981 914
MO 741 653 623 579
FC 440 378 358 335
FC: families contained ASD-diagnosed females (female-containing); MO: families
contained ASD-diagnosed males.
aA larger fraction of families tends to be removed from the more stringently diagnosed groups
(narrow and broad) and from female-containing families, but neither trend approaches
significance when the data are fitted to a log-linear model.
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After removing ‘CNV families’, the data becomes suggestive for
linkage in two regions, 11p12–p13 and 15q23–25.3 (Fig. 3), contrary
to results from all broad families. The most noteworthy impact occurs
for the batch method, which removes the greatest fraction of families.
When families removed versus retained by the batch method are
contrasted for identity-by-descent (IBD), heterogeneity is modest
except for the 15q25.3 region (Fig. 3).
The 4:1 ratio of affected males to females, higher reported recur-
rence risk for siblings of female versus male probands8 and published
literature30,31 suggest that a useful partition of the ASD families would
be whether they contained affected females (‘female-containing’) or
only affected males (‘male-only’). Thus, we partitioned the families
according to these criteria and recomputed linkage traces for each of
the three nested groupings of diagnosis (Fig. 4). Consistent with
theory32, the female-containing families seem to be more informative
for linkage. For instance, for the narrow diagnostic scheme, linkage
traces cross the suggestive threshold three times, at 5p15.33, 9p24.1
and 11p13–12, whereas the traces do not approach this threshold for
male-only families. Linkage traces for male-only families cross the
suggestive threshold only for the most inclusive diagnostic level
(5q12.3 and 9q33.3; Fig. 4) but not at the same locations as female-
containing families. Although the differences between female-contain-
ing and male-only families in terms of linkage could be due to chance,
tests of heterogeneity of IBD uncover substantial heterogeneity in 9p,
9q and 11p and modest heterogeneity in 5q (Fig. 4).
Dividing the data into subsets according to
presence of CNVs and according to sex of
affected individuals seems to generate more
informative linkage signals. To test whether
combining both approaches to form subsets
would also be useful, we used the broad
diagnostic grouping. Linkage using these
six subsets (Table 3), female-containing ver-
sus male-only by three levels of CNV discov-
ery, provides even more support for a risk
locus in the vicinity of 11p12–p13 in female-
containing families (Fig. 5). Removing
families based on the batch method of
CNV discovery nominates a 15q23 locus in
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Figure 3 Highlighted linkage results due to removing families in which
affected individuals carry putative CNVs. Results from all families (ignoring
CNVs) noted by the cyan line; results from the filtered set, the orange line;
results from the plate set, red line; and results from the batch set, black
line. Families all fall in the broad diagnostic category. Complete results are
in Supplementary Figure 2. For chromosome 11, the maximum occurs in
11p13 (Zlr ¼ 3.33 at rs2421826). For chromosome 15, there are two up-
crossings: the smaller peak occurs at 15q23 (Zlr ¼ 3.19 at rs1372828) and
the larger at 15q25.3 (Zlr ¼ 3.41 near rs1433452). For families removed
versus those retained, heterogeneity of estimated identity-by-descent was
tested in the ±5-cM linkage region surrounding each peak and reported as
regional minimum heterogeneity P value m-P (11p12–p13, m-P ¼ 0.074;
15q23, m-P ¼ 0.044; 15q25.3, m-P ¼ 0.004).
Figure 4 Linkage peaks by male-only versus
female-containing families, based on levels of
diagnostic certainty. For female-containing
families and narrow diagnosis, peaks localize
to 5p14.33 (Zlr ¼ 3.41 at rs1968011;
m-P ¼ 0.141), 9p24.1 (Zlr ¼ 3.21 at
rs1340513; m-P ¼ 0.0007) and 11p13
(Zlr ¼ 3.77 at rs1358054; m-P ¼ 0.008);
for female-containing families and broad
diagnosis, to 9p24.1 (Zlr ¼ 3.59 at rs722628;
m-P ¼ 0.006) and 11p13 (Zlr ¼ 3.90 at
rs1358054; m-P ¼ 0.015) and for all female-
containing families, to 11p12 (Zlr ¼ 3.63 at
rs1039205; m-P ¼ 0.078). For all male-only
families, peaks localize to 5q12 (Zlr ¼ 3.26
at rs673743; m-P ¼ 0.019) and 9q33.3
(Zlr ¼ 3.30 at rs536861; m-P ¼ 0.0005).
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female-containing families (Fig. 5), and the maximum at 11p12–p13
approaches genome-wide significance (4.03 versus 4.1). Affected
individuals in female-containing families have a slightly elevated rate
of CNV detection (2%–3%) relative to male-only families, regardless
of CNV-calling method, and the broad diagnostic group of families
has a similarly elevated rate of CNV detection relative to hASD; the
‘paired’ rates are not significantly different, nor is the interaction of
these variables a significant predictor of the presence or absence of a
detected CNV (data not shown).
Families participating in the AGP studies vary in their ancestry. To
evaluate whether linkage would be strengthened by analyzing families
of relatively homogeneous ancestry, we restricted the sample to
‘European ancestry’, as inferred by principal components33 of SNP
genotypes. We inferred that all founders in 995/1,168 (85.2%) families
were of European origin (Supplementary Fig. 3 online); inferred
ancestry agreed with available self-reports (99.6%). Using this sample,
we repeated all linkage analyses in Figures 1 and 3–5.
Exclusion of non-European families generally had only a modest
impact on the results (see Supplementary Fig. 4 online for complete
results). Linkage traces at chromosome 11p remained prominent,
especially for female-containing families, although the linkage region
for 11p was much broader. By using the batch results to remove ‘CNV
families’, a new region of suggestive linkage emerged: namely, 4q31.22,
which also shows substantial heterogeneity of IBD (P o 0.00006)
between retained and removed families. For all male-only families, the
normalized likelihood ratio statistic for linkage (Zlr) ¼ 3.85 at 9q33.3.
In addition, previously reported locations for linkage, especially 2q
and 7q, gained more support from this ‘European’ subset of the data.
For example, linkage traces approached genome-wide suggestive
linkage at 2q31.1 (female-containing, narrow)
and 7q22.2 (male-only, broad).
DISCUSSION
The results obtained from scanning the gen-
omes of the largest cohort of ASD families yet
assembled delineate a new understanding of
the genetic basis for this complex disorder. It
is widely understood that risk for ASD arises
in small part from chromosomal copy num-
ber abnormalities (CNAs), such as duplica-
tions of chromosome 15q11–q13. Yet, for
nuclear families containing two or more
affected individuals and prescreened for
microscopic CNAs, linkage analyses have
implicitly assumed other CNAs would have
little if any role in the heritable component
of ASD. Our CNV results lie in stark contrast with this view. Instead,
we find an appreciable number of families that could be assessed
(68/590 or 11.5%, 36/476 or 7.6% and 34/350 or 9.7% in the batch,
plate or filter analyses, respectively; Table 2), in which all affected
individuals share possibly detrimental abnormalities (that is, possible
CNAs). Owing to the relatively wide and uneven spacing of SNPs and
our conservative approach of calling CNVs, we have missed many
other events of this kind. By contrast, we also find a number
of families in which only one of the affected relatives has a detected
CNA. One possible implication of this finding is that, in these
cases, relevant CNVs might be risk factors and not the only causal
event. It is also possible that closely related individuals are
etiologically heterogeneous.
With the goal of minimizing heterogeneity that might confound
mapping of major loci conferring risk for ASDs, we invested sub-
stantial effort to standardize all phases of this multicenter project,
including phenotypic assessment, sample ascertainment, genotyping
and analysis. Linkage analyses based on a three-level diagnostic
scheme produce suggestive evidence for linkage in the vicinity of
11p12–p13 (Fig. 1) for one level: all families. Relative to appropriate
baseline, evidence for linkage at 11p12–p13 is amplified in select
subsets of the data: (i) subsets obtained by removing families contain-
ing one or more affected individuals inferred to carry CNV (Fig. 3);
(ii) the set of families containing affected females (Fig. 4) and
(iii) subsets of families based on both sex of affected individuals
and presence of CNVs (Fig. 5). For the subset of female-containing
families without affected individuals who carry CNVs, the maximum
Zlr increases to 4.03. We believe these explorations motivate thorough
fine-mapping of the 11p12–p13 region. Modest peaks for linkage have
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Figure 5 The effect on linkage of splitting
families into female-containing and male-only
families while also removing families in which
affected individuals putatively carry CNVs. For
female-containing families and the filtered
subset, peaks localize to 9p24.1 (Zlr ¼ 3.32 at
rs1575284; m-P ¼ 0.105) and 11p12 (Zlr ¼
3.90 at rs1039205; m-P ¼ 0.411); for female-
containing and the plate-by-plate subset, to
9p24.1 (Zlr ¼ 3.28 at rs1821892; m-P ¼
0.295) and 11p12 (Zlr ¼ 3.48 at rs1039205;
m-P ¼ 0.111); and for female-containing families
and the batch subset, to 11p13 (Zlr ¼ 4.03 at
rs1358054; m-P ¼ 0.014) and 15q23 (Zlr ¼
3.30 at rs1433452; m-P ¼ 0.044).
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been observed previously for this region, but 11p12–p13 has not been
a major focus for discovery of autism risk loci.
Several regions have been featured prominently in previous linkage
analyses: namely 2q, 7q and 17q. Of these regions, 2q and 7q garner
modest linkage support from families of European ancestry (Supple-
mentary Fig. 4), whereas the 17q linkage region does not. The largest
linkage signal on 2q, Zlr ¼ 3.1, occurs for female-containing families in
2q31.1; the largest signal on 7q, Zlr ¼ 3.1, occurs for male-only families
in 7q22.3. Several explanations are plausible for these results. First, the
previous linkages could be false positives. Second, for linkage studies of
complex disorders, statistics for identified linkage regions tend to be
biased upward relative to that expected from the linked risk loci.
Because of this bias, combining samples with mixed evidence for
linkage and adding new families, as done here, will often diminish pre-
viously identified linkage signals. Third, studies could have collec-
ted samples that differ in heritable features tied to risk loci, exaggerating
the heterogeneity already inherent in ASD. Stochastic variation com-
bined with this heterogeneity could overwhelm the linkage signal.
None of our linkage results can be interpreted as ‘statistically
significant’ because we have performed numerous analyses of the
data. In fact, we performed 18 linkage analyses on the full sample and
18 using families of European ancestry. Because many of these analyses
were performed on overlapping subsets of the data, we effectively
performed the equivalent of four to five independent genome scans34.
Our CNV analyses detect a hemizygous deletion of coding exons
from NRXN1 for a pair of affected siblings. Without other informa-
tion, this finding might not be especially meaningful, in particular
because of the prevalence of CNVs in the genome21. However, the
alteration is a de novo event, and others23 have reported rare missense
variants in NRXN1 in individuals with ASD that are not found in over
500 controls. Moreover, NRXN1 interacts with neuroligins, for which
rare mutations apparently generate risk for ASDs and mental retarda-
tion14,15. Therefore, we have evaluated transmissions in our families
for four NRXN1 SNPs (rs1363036, rs930752, rs1377238, rs2018909).
Using the FBAT35 empirical statistic, we have tested transmissions
under additive and dominant models in all families and in the broad
subset (dominant and recessive models are indistinguishable in this
analysis). For all families, biased transmission is significant at two loci
under the dominant model: the minor allele of rs1363036 (P ¼
0.0091) and the major allele of rs930752 (P ¼ 0.025). (Only
rs930752 showed significantly biased transmission under the additive
model (P¼ 0.014).) These SNPs are in modest LD (r2¼ 0.048). In the
broad subset, results are stronger for rs1363036 (dominant, P ¼
0.0041) but are weaker for rs930752 (dominant, P ¼ 0.076; additive,
P ¼ 0.072). These two SNPs, separated by 88 kb, are intronic and are
unlikely to convey risk directly.
Accumulating evidence thus implicates a role for neurexins and
neuroligins in ASDs. For communication of signal between neurons,
postsynaptic receptors must oppose neurotransmitter release sites on
presynaptic axons. Neurexins have been shown to induce postsynaptic
differentiation in contacting dendrites, while neuroligins induce
presynaptic differentiation in glutamatergic axons36. The neurexin-
neuroligin link is fundamentally important for glutamatergic
synaptogenesis (and, apparently, GABAergic synaptogenesis36,37).
Moreover, aberrant glutamate function is often cited as an important
element of risk for ASDs38,39, a hypothesis compatible with its role
as the major excitatory neurotransmitter and critical factor in
brain development40. Autism-like behaviors and diagnoses of autism
are common for individuals with either Fragile-X syndrome or
tuberous sclerosis, both of which are associated with dysregulated
glutamate signaling41,42.
Is oligogenic or ‘major gene’ variation associated with other
glutamate-related genes? In addition to our results, intriguing evi-
dence for association has been found for the mitochondrial aspartate/
glutamate carrier SLC25A12 (on 2q31) and GRIK2 (ref. 13). Still, the
protein product of SLC25A12 is a mitochondrial aspartate-glutamate
carrier not known to affect glutamatergic synaptic function. Knockout
of SLC25A12 in mice impairs myelination of neuronal cells resulting
from limitations to aspartate delivery, not glutamate43. The protein
product of GRIK2, GluR6, is an ionotropic kainate receptor that
affects neuronal development. Based on its mapping to 6q16.3, it is
not a positional candidate according to our results. For female-
containing families, however, linkage results are modestly positive
(Zlr ¼ 1.9 for all families and families of European ancestry; Zlr ¼
B2.40 for families retained using the batch method of CNV calling).
The UCSC Genome Browser lists 168 genes with descriptions
containing the keyword ‘glutamate’. Many fall in linkage regions,
including 11p13–12 (SLC1A2 and PRRG4), 2q31 (SLC25A12),
4q28.3 (SLC7A11), 7q21.3 (SLC25A13), 9p24.2 (SLC1A1), 9q34.11
(FGPS) and 15q25.2 (HOMER2). Of ten glutamate solute carriers, half
fall in the cited linkage regions (keywords ‘glutamate’ + ‘solute’ +
‘carrier’), but not all are related to glutamatergic synaptic function.
SLC1A1 and SLC1A2 fall close to linkage peaks, and their protein
products affect glutamate synapse function and brain development;
thus, they are excellent targets for positional candidate gene analyses.
METHODS
Linkage screening set. A SNP-based genome scan was conducted using the
Affymetrix 10K v2 SNP array. Genotyping was contracted to the Translational
Genomics Research Institute (TGEN). TGEN genotyped DNA samples falling
into 1,496 nominal families, of which 1,168 could be used for linkage. Written
permission was received from all adult participants and for all younger
participants; procedures were approved by institutional review boards of all
participating institutions.
Strategy for linkage analysis. For linkage analyses, we grouped families into
three diagnostic classes: narrow, broad and heterogeneous ASD (hASD). To
qualify for the narrow class, two or more affected individuals had to meet
criteria for autism on both the ADI-R18 and the ADOS18. For the broad
category, at least one individual had to meet ADI-R criteria for autism and
ADOS criteria for autism or ASD. At least one other family member had to
meet criteria for impairment on the social or communication domains of the
ADI-R and meet criteria for at least ASD on the ADOS. The hASD families
were completely independent of the broad and narrow categories but
were combined with the broad set to analyze linkage in all families. The
hASD families consisted largely of either families that met ADI-R criteria for
ASD or autism18 but that did not undergo ADOS evaluation or families with
multiple individuals per family who met ASD criteria by ADOS and demon-
strated impairment on the social or communication domains of the ADI-R
but did not meet full criteria for autism on the ADI-R. In addition to diagnostic
categories, families were divided into subsets based on male-only or female-
containing status.
Genetic quality control, tag SNP selection and ancestry. We evaluated three
features of data quality: namely, degree of missing genotypes (missingness),
mendelian errors and Hardy-Weinberg equilibrium (HWE). Individuals (20%)
and loci (10%) with substantial missing data were not considered for linkage
analyses because these features usually indicate poor DNA quality and problems
with genotype calls, respectively. Likewise, loci with minor allele frequency
(MAF) o 0.05 were discarded.
Mendelian errors were evaluated using PEDCHECK44. Loci showing multiple
mendelian errors—for correct family structure—were discarded for linkage
testing. To overcome possible problems arising owing to ancestry, we first
selected tag SNPs and then evaluated HWE with the large sample inferred to be
of homogeneous European ancestry. We analyzed linkage disequilibrium (LD)
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using HCLUST45, selecting tag SNPs to represent clusters of others in substantial
LD (r2 4 0.8). We chose those that were highly correlated with the other SNPs
in the cluster; we estimated ancestry by using principal component analyses33
and evaluated HWE using parental data. Loci were not used for analyses if
HWE was rejected at a P-valueo 0.005. Finally, we used MERLIN46 to infer likely
genotyping errors on the basis of apparent genetic recombination. When
genotypes were likely to be errors (P o 0.01), they were set to ‘missing’.
Linkage analysis. We used the BLUE method47 to estimate allele frequencies.
Linkage was estimated from the entire set of SNPs using MERLIN46 and the
exponential S-all statistic. Linkage was also estimated by using MERLIN46 and
ALLEGRO
48 from tag SNPs. We found virtually no difference in results using tag
SNPs or all SNPs, with or without using the options in MERLIN to handle LD. We
analyzed heterogeneity of linkage between strata using the methods of ref. 49,
which test for significant differences in shared IBD among affected siblings in
families. We computed heterogeneity statistics in each region or setting in
which a linkage trace crossed the threshold for suggestive linkage.
CNV assessment. CNVs were inferred from Affymetrix 10K array scans using
dChip 2006 software (DNA Chip Analyzer)50. We have also used other
algorithms, and the data will be posted at the Autism Chromosome Rearrange-
ment Database as it is validated. Initially, 7,610 scans were available (this
number exceeds the 6,709 samples genotyped for linkage since the CNV
experiments continued after the initial data freeze). We excluded those samples
with a genotype call rate o92% and/or an array percentage outlier of 45%,
leaving 5,997 experiments suitable for CNV analyses. For the ‘batch’ analysis,
we grouped the arrays into six cohorts of 1,000 samples each. The median
probe intensities for the arrays varied greatly (o100 to41,000), indicating the
need for normalization to compare signals. Arrays were normalized at the
probe intensity level using invariant set normalization to a baseline array within
each group of 1,000 experiments50. A signal value was then calculated for each
SNP using a model-based method and averaged across all samples for each SNP
to obtain the mean signal of a diploid genome. The observed raw copy number
was then defined and copy number inferred for each individual or SNP using a
Hidden Markov Model50. As samples were submitted in 96-well plate formats
and arrays were processed in the same manner, the ‘batch’ analysis contained
plate-specific noise, apparently leading to many false positive CNV calls. In an
attempt to increase the signal-to-noise ratio, we analyzed arrays in a 96-well
plate-specific manner. For example, we excluded 12 plates having fewer than
40 samples after the initial filtering, leaving 5,823 scans for the plate analysis.
Arrays were normalized within each set and copy number calculated in the
same manner as was for the ‘batch’ analysis. We also excluded those samples
with more than ten CNVs per sample from all analyses to avoid calling a
high number of false positives. Because we had family data, certain CNV
could be tentatively confirmed by using the family structure and mendelian
errors (although the original CNV calls were blind to family status). Using these
data as a benchmark, the ‘plate’ analysis produced a cleaner data set than
the ‘batch’ analysis and was therefore parsed further using a combination of
more stringent thresholds (fewer than five CNVs per sample) and manual
curation of the raw data to give a ‘filtered’ data set. The inferred CNVs for all
three data sets were interpreted on several levels. We also completed similar
analysis for the X chromosome but did not include the results, as only 263
SNPs covered this segment of the genome (40 CNVs were found). Called CNVs
were also examined for overlap with genomic features including mapped
chromosome rearrangement breakpoints annotated in the Autism Chromo-
some Rearrangement Database and polymorphic CNVs in the Database of
Genomic Variants. For all three analyses, affected individuals and families with
CNVs that did not have complete overlap with the DGV were removed from
linkage analysis.
Accession codes. Gene Omnibus Expression (GEO): raw data from the
Affymetrix 10K experiments, GSE6754.
URLs. Autism Chromosome Rearrangement Database: http://projects.tcag.ca/
autism/; Database of Genomic Variants: http://projects.tcag.ca/variation/; GEO:
http://www.ncbi.nlm.nih.gov/geo/.
Note: Supplementary information is available on the Nature Genetics website.
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Corrigendum: Mapping autism risk loci using genetic linkage and chromo-
somal rearrangements
The Autism Genome Project Consortium
Nat. Genet. 39, 319–328 (2007); published online 18 February; corrected after print 26 September 2007
In the version of this article originally published, Kacie J. Meyer (University of Iowa, Iowa City) was inadvertently omitted from the list of authors, 
and the names of three authors (Frederieke Koop, Marjolein Langemeijer and Channa Hijmans) were misspelled. Also, the third sentence of the 
abstract incorrectly stated that 1,168 families were analyzed. The correct number is 1,181 families. Finally, the last paragraph of the Discussion 
mistakenly identified one of the linkage regions as 11q13-12. This should read 11p13-12. These errors have been corrected in the HTML and PDF 
versions of the article.
Corrigendum: Nuclear reprogramming of cloned embryos and its implica-
tions for therapeutic cloning
Xiangzhong Yang, Sadie L Smith, X Cindy Tian, Harris A Lewin, Jean-Paul Renard & Teruhiko Wakayama
Nat. Genet. 39, 295–302 (2007); published online 26 February; corrected after print 26 September 2007
In the version of this article initially published, the legend for Figure 1 is inaccurate. The original legend for Figure 1c failed to note that the 
cells derived from cattle embryos were embryonic stem cell (ESC)-like or trophectoderm cell colonies. The full legend for Figure 1c should read 
“Therapeutic cloning: percentage ESC line derivation (mice) or ESC-like or trophectoderm cell colony formation (cattle) from embryos derived 
from both IVF and nuclear transfer.” This error has been corrected in the HTML and PDF versions of the article.
Corrigendum: Variation in FTO contributes to childhood obesity and severe 
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Christian Dina, David Meyre, Sophie Gallina, Emmanuelle Durand, Antje Körner, Peter Jacobson, Lena M S Carlsson, Wieland Kiess, 
Vincent Vatin, Cecile Lecoeur, Jérome Delplanque, Emmanuel Vaillant, François Pattou, Juan Ruiz, Jacques Weill, Claire Levy-Marchal,  
Fritz Horber, Natascha Potoczna, Serge Hercberg, Catherine Le Stunff, Pierre Bougnères, Peter Kovacs, Michel Marre, Beverley Balkau, 
Stéphane Cauchi, Jean-Claude Chèvre & Philippe Froguel
Nat. Genet. 39, 724–726 (2007); published online 13 May; corrected after print 26 September 2007
In the version of this article initially published, the authors failed to acknowledge that recruitment of obese cases was supported by both Assistance-
Publique Hôpitaux de Paris and Centre National de la Recherche Scientifique. This error has been corrected in the PDF version of the article.
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